Rafferty Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$381K Buy
77,644
+13,941
+22% +$74.9K ﹤0.01% 938
2026
Q2
$390K Sell
63,703
-28,601
-31% -$187K ﹤0.01% 957
2026
Q1
$638K Buy
+92,304
New +$712K ﹤0.01% 858
2023
Q3
– Sell
-220,097
Closed -$1.45M – 1107
2023
Q2
$1.45M Sell
220,097
-9,989
-4% -$64K 0.01% 729
2023
Q1
$1.56M Buy
230,086
+89,946
+64% +$632K 0.01% 676
2022
Q4
$1.04M Buy
140,140
+2,974
+2% +$29K 0.01% 745
2022
Q3
$1.36M Buy
137,166
+52,321
+62% +$552K 0.01% 594
2022
Q2
$925K Sell
84,845
-87,477
-51% -$906K 0.01% 676
2022
Q1
$1.95M Buy
172,322
+42,125
+32% +$554K 0.01% 603
2021
Q4
$2.04M Buy
130,197
+48,558
+59% +$846K 0.01% 654
2021
Q3
$1.4M Buy
81,639
+8,428
+12% +$148K 0.01% 733
2021
Q2
$1.58M Sell
73,211
-27,990
-28% -$501K 0.01% 747
2021
Q1
$1.52M Buy
101,201
+77,871
+334% +$1.26M 0.01% 685
2020
Q4
$307K Sell
23,330
-42,064
-64% -$506K ﹤0.01% 803
2020
Q3
$632K Buy
65,394
+30,373
+87% +$325K 0.01% 657
2020
Q2
$401K Buy
+35,021
New +$397K 0.01% 762
2020
Q1
– Sell
-52,858
Closed -$867K – 803
2019
Q4
$867K Sell
52,858
-86,598
-62% -$1.31M 0.01% 581
2019
Q3
$1.85M Sell
139,456
-6,028
-4% -$84K 0.03% 408
2019
Q2
$2.05M Sell
145,484
-19,368
-12% -$308K 0.04% 413
2019
Q1
$3.03M Buy
+164,852
New +$3.76M 0.05% 220

Other funds holding VNDA

Rafferty Asset Management's VNDA Position: Q3 2026 in Review

Rafferty Asset Management increased its Vanda Pharmaceuticals (VNDA) stake by 22% in Q3 2026, buying an estimated $74.9K and bringing the position to 77,644 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Rafferty Asset Management first reported a position in VNDA in Q1 2019 and has held it in 20 quarters since. The position peaked at $3.03M in Q1 2019. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • Rafferty Asset Management held 77,644 shares of Vanda Pharmaceuticals worth $381K as of Q3 2026.
  • Rafferty Asset Management bought 13,941 Vanda Pharmaceuticals shares in Q3 2026, an estimated $74.9K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #938 holding.
  • Rafferty Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2019 and has held it in 20 quarters since.
  • Rafferty Asset Management's Vanda Pharmaceuticals position peaked at $3.03M in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.